{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.5","upperLimit":"73.9","value":"64.7"},{"groupId":"OG001","lowerLimit":"44.2","upperLimit":"59.7","value":"50.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs \\> 12 months). The median duration of follow-up is calculated by the reverse Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients enrolled in the study who did not receive cytoreductive surgery and included in the surgery analysis","id":"OG000","title":"No Cytoreductive Surgery"},{"description":"All patients enrolled in the study who received secondary cytoreductive surgery and were included in the surgery analysis","id":"OG001","title":"Cytoreductive Surgery"}],"paramType":"MEDIAN","populationDescription":"All patients who were eligible for the surgery analysis (data were combined and analyzed according to randomized surgical assignment, regardless of chemotherapy regimen, as pre-specified in the study protocol)","reportingStatus":"POSTED","timeFrame":"The time frame is 82.5 months (median duration of follow-up)","title":"To Determine if Surgical Secondary Cytoreduction in Addition to Adjuvant Chemotherapy Increases the Duration of Overall Survival in Patients With Recurrent Platinum Sensitive Epithelial Ovarian Cancer, Peritoneal Primary or Fallopian Tube Cancer","type":"PRIMARY","unitOfMeasure":"Months"}